MedTrace Logo

Study of Picoplatin Efficacy After Relapse

NCT00465491 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2009-04-14

No results posted yet for this study

Summary

Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options. This study is designed to compare the efficacy and safety of picoplatin plus Best Supportive Care (BSC) with BSC alone. Best Supportive Care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side-effects of anti-cancer treatments.

Conditions

Interventions

DRUG

picoplatin

IV picoplatin 150mg/m2 q3wk

OTHER

best supportive care

best supportive care

Sponsors & Collaborators

  • Poniard Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dr. Hazel Breitz, M.D. · Poniard Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-05-31

Countries

  • Argentina
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Chile
  • Croatia
  • Hungary
  • India
  • Latvia
  • Montenegro
  • Poland
  • Romania
  • Russia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00465491 on ClinicalTrials.gov